Skip to main content
Premium Trial:

Request an Annual Quote

New York State Grants Conditional Approval to KSL Diagnostics for COVID-19 Antibody Assay

NEW YORK ─ SQI Diagnostics on Thursday announced that the New York State Department of Health has granted conditional approval to its diagnostic testing partner, KSL Diagnostics, for SQI Diagnostics' Exact COVID-19 Antibody Test.

With the approval, Buffalo, New York-based KSL can test blood specimens received from anywhere in the US, the firm's president and CEO, Kevin Lawson, said in a statement.

According to Toronto-based SQI, its test provides semi-quantitative measurements of six antibodies produced by the immune system in response to exposure to the SARS CoV-2 virus or a COVID-19 vaccination. The test, which uses a fingerstick of blood collected in the home or elsewhere, can be ordered through Azova, a telemedicine testing company, SQI said.

SQI noted that it sells Health Canada-approved testing kits for RT-PCR-based SARS-CoV-2 testing and point-of-care antigen-based SARS-CoV-2 testing, and it has applied to Health Canada for its Rali-Dx IL-6 test, a hospital-based respiratory triage assay for COVID-19-positive patients.